OBJECTIVES: To compare overall and prostate cancer-specific survival, using the Detroit Surveillance, Epidemiology, and End Results registry data, among 8679 Detroit area black and white men with localized or regional stage prostate cancer diagnosed from 1988 to 1992 to determine whether racial disparities in long-term survival remained after adjusting for treatment type and socioeconomic status (SES). METHODS: The cases were geocoded to the census block-group, and SES data were obtained from the 1990 U.S. Census. Cox proportional hazards regression analysis was used to estimate the hazard ratio of death from any cause. The median follow-up was 16.5 years. RESULTS: Of the 7770 localized stage cases (22% black and 78% white) and 909 regional cases (24% black and 76% white), black men were more likely to receive nonsurgical treatment (P < .001) and to be of low SES (P < .0001). The survival analyses were stratified by stage. For both stages, black men had poorer survival than white men in the unadjusted model. The adjustment for age and tumor grade had little effect on the survival differences, but adjustment for SES and treatment removed the survival differences. CONCLUSIONS: Low SES and nonsurgical treatment were associated with a greater risk of death among men with prostate cancer, explaining much of the survival disadvantage for black men with prostate cancer.
OBJECTIVES: To compare overall and prostate cancer-specific survival, using the Detroit Surveillance, Epidemiology, and End Results registry data, among 8679 Detroit area black and white men with localized or regional stage prostate cancer diagnosed from 1988 to 1992 to determine whether racial disparities in long-term survival remained after adjusting for treatment type and socioeconomic status (SES). METHODS: The cases were geocoded to the census block-group, and SES data were obtained from the 1990 U.S. Census. Cox proportional hazards regression analysis was used to estimate the hazard ratio of death from any cause. The median follow-up was 16.5 years. RESULTS: Of the 7770 localized stage cases (22% black and 78% white) and 909 regional cases (24% black and 76% white), black men were more likely to receive nonsurgical treatment (P < .001) and to be of low SES (P < .0001). The survival analyses were stratified by stage. For both stages, black men had poorer survival than white men in the unadjusted model. The adjustment for age and tumor grade had little effect on the survival differences, but adjustment for SES and treatment removed the survival differences. CONCLUSIONS: Low SES and nonsurgical treatment were associated with a greater risk of death among men with prostate cancer, explaining much of the survival disadvantage for black men with prostate cancer.
Authors: Kathryn E Richert-Boe; Sheila Weinmann; Jean A Shapiro; Benjamin A Rybicki; Shelley M Enger; Stephen K Van Den Eeden; Noel S Weiss Journal: Urology Date: 2008-02-15 Impact factor: 2.649
Authors: Jacob H Cohen; Victor J Schoenbach; Jay S Kaufman; James A Talcott; Anna P Schenck; Sharon Peacock; Michael Symons; M Ahinee Amamoo; William R Carpenter; Paul A Godley Journal: Cancer Causes Control Date: 2006-08 Impact factor: 2.506
Authors: David M Latini; Eric P Elkin; Matthew R Cooperberg; Natalia Sadetsky; Janeen Duchane; Peter R Carroll Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: Thomas D Denberg; Fernando J Kim; Robert C Flanigan; Diane Fairclough; Brenda L Beaty; John F Steiner; Richard M Hoffman Journal: Med Care Date: 2006-12 Impact factor: 2.983
Authors: Arnaud Merglen; Franz Schmidlin; Gerald Fioretta; Helena M Verkooijen; Elisabetta Rapiti; Roberto Zanetti; Raymond Miralbell; Christine Bouchardy Journal: Arch Intern Med Date: 2007-10-08
Authors: Tim E Byers; Holly J Wolf; Katrina R Bauer; Susan Bolick-Aldrich; Vivien W Chen; Jack L Finch; John P Fulton; Maria J Schymura; Tiefu Shen; Scott Van Heest; Xiang Yin Journal: Cancer Date: 2008-08-01 Impact factor: 6.860
Authors: Xianglin L Du; Shenying Fang; Sally W Vernon; Hashem El-Serag; Y Tina Shih; Jessica Davila; Monica L Rasmus Journal: Cancer Date: 2007-08-01 Impact factor: 6.860
Authors: Xianglin L Du; Shenying Fang; Ann L Coker; Maureen Sanderson; Corrine Aragaki; Janice N Cormier; Yan Xing; Beverly J Gor; Wenyaw Chan Journal: Cancer Date: 2006-03-15 Impact factor: 6.860
Authors: Jenine K Harris; Julianne Cyr; Bobbi J Carothers; Nancy B Mueller; Victoria V Anwuri; Aimee I James Journal: Am J Public Health Date: 2011-05-12 Impact factor: 9.308
Authors: David J Riedel; Evelyn Ivy W Mwangi; Lori E Fantry; Carla Alexander; Mian B Hossain; C David Pauza; Robert R Redfield; Bruce L Gilliam Journal: AIDS Date: 2013-04-24 Impact factor: 4.177
Authors: Rachel Jimenez; Baohui Zhang; Steven Joffe; Matthew Nilsson; Lorna Rivera; Jan Mutchler; Christopher Lathan; M Elizabeth Paulk; Holly G Prigerson Journal: J Palliat Med Date: 2013-02-05 Impact factor: 2.947
Authors: Alex Tsodikov; Roman Gulati; Tiago M de Carvalho; Eveline A M Heijnsdijk; Rachel A Hunter-Merrill; Angela B Mariotto; Harry J de Koning; Ruth Etzioni Journal: Cancer Date: 2017-04-24 Impact factor: 6.860
Authors: Dan P Zandberg; Sandy Liu; Olga Goloubeva; Robert Ord; Scott E Strome; Mohan Suntharalingam; Rodney Taylor; Robert E Morales; Jeffrey S Wolf; Ann Zimrin; Joshua E Lubek; Lisa M Schumaker; Kevin J Cullen Journal: Head Neck Date: 2015-06-30 Impact factor: 3.147